References

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update

10.1016/j.ard.2026.01.023 · 2026 · External reference

Unresolved reference

2021 · External reference

Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study

10.1093/rheumatology/keae607 · 2025 · External reference

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

10.1016/s2665-9913(24)00221-2 · 2025 · External reference

Trends in remission rates for rheumatoid arthritis in England and Wales: a population-level cohort study

10.1093/rheumatology/keaf233 · 2025 · External reference

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts

10.1136/rmdopen-2023-003027 · 2023 · External reference

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

10.1016/s0140-6736(16)30363-4 · 2016 · External reference

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis

10.1093/rheumatology/kep155 · 2009 · External reference

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

10.1002/art.21678 · 2006 · External reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

10.1136/ard.2009.126532 · 2010 · External reference

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

10.1002/art.21405 · 2005 · External reference

Remission is the ambition: can remission rates for new patients with rheumatoid arthritis finally be improved, at minimal cost?

10.1093/rheumatology/keaf130 · 2025 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

Unresolved reference

2024 · External reference

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

10.1002/jrsm.1045 · 2012 · External reference

Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis

10.1002/jrsm.1167 · 2016 · External reference

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

10.1136/bmj.m4328 · 2020 · External reference

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

10.1136/annrheumdis-2013-203440 · 2014 · External reference

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

10.1136/ard.2010.137703 · 2011 · External reference

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial

10.1136/annrheumdis-2019-216539 · 2020 · External reference

Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis

2017 · External reference

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials

10.1136/rmdopen-2016-000323 · 2016 · External reference

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis

10.1136/bmj.i1777 · 2016 · External reference

Comparative effectiveness of combining MTX with biologic drug therapy versus either MTX or biologics alone for early rheumatoid arthritis in adults: a systematic review and network meta-analysis

10.1007/s11606-019-05230-0 · 2019 · External reference

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

10.1016/s0140-6736(13)60250-0 · 2013 · External reference

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

10.1016/s0140-6736(19)30419-2 · 2019 · External reference

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

10.1002/art.34498 · 2012 · External reference

Psychological distress over 12 months post-diagnosis in an early inflammatory arthritis cohort

10.1093/rheumatology/keae276 · 2025 · External reference

Development of a clinical tool to identify patients with early inflammatory arthritis at high risk of employment loss: analysis from the National Early Inflammatory Arthritis Audit

10.1093/rap/rkaf149 · 2026 · External reference

2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis

10.1002/art.41752 · 2021 · External reference

Unresolved reference

2018 · External reference

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

10.1136/ard-2023-224116 · 2023 · External reference

Unresolved reference

2025 · External reference

Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial

10.1016/s2665-9913(26)00007-x · 2026 · External reference

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

10.1002/art.21675 · 2006 · External reference

Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study

10.1136/rmdopen-2019-000935 · 2019 · External reference

Cost-Effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis

10.1007/s12325-019-00986-7 · 2019 · External reference

Cost-effectiveness of biosimilars vs leflunomide in patients with rheumatoid arthritis

10.1001/jamanetworkopen.2024.18800 · 2024 · External reference